Read by QxMD icon Read

Psoriasis comorbidities

S González-Parra, E Daudén
Psoriasis is a chronic, systemic inflammatory disorder with multiple comorbidities. The most common comorbidities are mental disorders, especially depression, which can interact negatively with psoriasis to produce a dangerous vicious circle. Depression in psoriasis has traditionally been explained as a response to psychosocial factors and impaired quality of life. However, a new hypothesis linking depression and psoriasis through chronic inflammation offers insights that should help to understand and treat these diseases...
November 30, 2018: Actas Dermo-sifiliográficas
Khalaf Kridin, Michal Shani, Yochai Schonmann, Shani Fisher, Guy Shalom, Doron Comaneshter, Erez Batat, Arnon D Cohen
BACKGROUND: The coexistence of psoriasis and hidradenitis suppurativa (HS) has been described, but the association between these conditions is yet to be firmly established. OBJECTIVES: To study the association between psoriasis and HS using a large-scale real-life computerized database. METHODS: A cross-sectional study was conducted comparing the prevalence of HS among patients with psoriasis and among age-, sex- and ethnicity-matched control subjects...
November 28, 2018: Journal of the American Academy of Dermatology
Jashin Wu, April Armstrong, Rakesh Singh, Martin Cloutier, Marjolaine Gauthier-Loiselle, Patrick Gagnon-Sanschagrin, Dilek Arikan, Alan Fleischer, Annie Guérin, Arijit Ganguli
Objective: To assess the real-world risk of developing adverse medical conditions (AMCs) among patients with psoriasis treated with biologic therapies or conventional systemic/topical therapies (CST/topical). Methods: Adult patients with psoriasis were identified from the Truven MarketScan US claims database (2008 Q3–2015 Q3) and classified into cohorts based on treatment initiated on the index date (adalimumab [ADA], etanercept [ETN], ustekinumab [UST], infliximab [IFX], or CST/topical). Incident AMCs were identified while on treatment from diagnoses recorded in medical claims and included abnormal test results, infections, mental disorders, cardiovascular disease, malignancies (skin and non-skin), and respiratory disease...
November 1, 2018: Journal of Drugs in Dermatology: JDD
Patricia Shu Kurizky, Gladys Aires Martins, Jamille Nascimento Carneiro, Ciro Martins Gomes, Licia Maria Henrique da Mota
BACKGROUND: Psoriasis has a significant impact on quality of life (QoL). Sexual life can also be affected, with sexual dysfunction being reported by 25-70% of patients. OBJECTIVES: To determine the occurrence of sexual dysfunction and evaluate QoL in women with psoriasis. METHODS: This case-control study included women aged 18-69 years. The validated Brazilian Portuguese versions of the Female Sexual Function Index (FSFI) and of the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) were administered to all participants to assess sexual function and QoL, respectively...
November 2018: Anais Brasileiros de Dermatologia
Cacilda S Souza, Caio C S de Castro, Francisca R O Carneiro, Jane M N Pinto, Lincoln H Z Fabricio, Luna Azulay-Abulafia, Ricardo Romiti, Tania F Cestari, Cláudia E Suzuki, Priscila M Biegun, Luciana S Guedes, Luiza K M Oyafuso
Interest has increased in comorbidities associated with psoriasis and their effects on health-related quality of life (HRQoL). This study aimed to evaluate the prevalence of metabolic syndrome (MetS) and psoriatic arthritis (PsA) and to investigate HRQoL and the prevalence of hypertension, type 2 diabetes mellitus (T2DM), obesity and dyslipidemia. In a cross-sectional design, patients diagnosed with plaque psoriasis answered an interview and standardized questionnaires (Dermatology Life Quality Index questionnaire [DLQI], 36-Item Short Form Health Survey [SF-36] and EuroQol Five-Dimension Questionnaire Three-Level version [EQ-5D-3L])...
November 26, 2018: Journal of Dermatology
Abdelaal M Elkamshoushi, Salma S Omar, Amr M El Abd, Seham Z Hassan, Eman A Sultan, Eman Abd Elkawy
BACKGROUND: Psoriasis is a common multisystem inflammatory disease with several associated comorbidities. Serological markers to detect associated subclinical atherosclerosis in psoriatic patients are needed. We aimed to study serum endocan levels in psoriasis vulgaris and its relation to severity of psoriasis, systemic inflammation, associated atherosclerosis, obesity, and the possible factors affecting its level in psoriatic patients. METHODS: This study was conducted on 30 moderate-severe psoriasis vulgaris patients and 30 healthy controls...
November 23, 2018: International Journal of Dermatology
Ying-Xiu Dai, Ming-Chun Hsu, Hsiao-Yun Hu, Yun-Ting Chang, Tzeng-Ji Chen, Chung-Pin Li, Chen-Yi Wu
Background : Previous studies showed conflicting results regarding the mortality risk in psoriasis patients with respect to disease severity and presence of psoriatic arthritis. This study aimed to determine the mortality risk in patients with mild and severe psoriasis and patients with psoriatic arthritis (PsA). Methods : A nationwide population-based cohort study was conducted based on data from the Taiwan National Health Insurance Research Database between 2002 and 2012. Incident psoriasis subjects were classified into two groups: psoriasis without arthritis and psoriasis with arthritis...
November 22, 2018: International Journal of Environmental Research and Public Health
Arvin Ighani, Arun C R Partridge, Neil H Shear, Charles Lynde, Wayne P Gulliver, Cathryn Sibbald, Patrick Fleming
INTRODUCTION: Many international guidelines for management of psoriasis exist and most have variations in grading evidence quality, strength of recommendations, and dosing. The objective of our review is to compare international guidelines published in the United Kingdom, Canada, Europe, and the United States for the management of moderate-to-severe plaque psoriasis. METHODS: We conducted a literature review on systemic therapies and phototherapy for moderate-to-severe plaque psoriasis in adult patients...
November 21, 2018: Journal of Cutaneous Medicine and Surgery
Andrea Chiricozzi, Luca Antonioli, Salvatore Panduri, Matteo Fornai, Marco Romanelli, Corrado Blandizzi
Psoriasis is a chronic inflammatory skin disorder pathogenically mediated by multiple cytokines, including interleukin (IL)-23, IL-17, and TNF. An emerging class of therapeutics that selectively blocks IL-23 has been developed. Among these new agents, risankizumab is now being investigated in phase III clinical trials, and the preliminary data are promising in inducing an excellent clinical response. Areas covered: This review aims to describe the pathogenic role of IL-23 in psoriasis and to collect clinical data related to the efficacy and safety of risankizumab, an anti-IL-23p19 agent, in the treatment of psoriasis...
November 21, 2018: Expert Opinion on Biological Therapy
Christoffer Blegvad, Anne-Marie Nybo Andersen, Abdulfatah Adam, Claus Zachariae, Lone Skov
Psoriasis is associated with cardiometabolic comorbidity; however, whether this is due to common lifestyle-related risk factors is unclear. This study investigated the association between psoriasis and cardiometabolic comorbidity, taking body mass index and smoking into account. The population comprised expectant mothers in the Danish National Birth Cohort (established 1996-2002). During pregnancy, the women were asked about physician-diagnosed psoriasis. Any association with self-reported cardiometabolic comorbidity 11 years later was assessed using logistic regression...
November 21, 2018: Acta Dermato-venereologica
Chase W Kwon, Richard G Fried, Yasmine Nousari, Christopher Ritchlin, Francisco Tausk
Psoriasis is a chronic inflammatory disorder characterized by substantial psychiatric comorbidity. Historically, anecdotal observations have suggested that psychosocial distress can trigger flares of psoriasis, but over the past several decades, high-quality data from experimental studies support the assertion that stress plays a critical role in the pathogenesis of psoriasis. There may be a subset of patients unable to elicit an appropriate immunosuppressive response to stress through upregulation of cortisol, with resultant exacerbation of their psoriasis...
November 2018: Clinics in Dermatology
M Augustin, R Sommer, N Kirsten, A Danckworth, M A Radtke, K Reich, D Thaci, W H Boehncke, A Langenbruch, U Mrowietz
BACKGROUND: In psoriasis, a variety of different phenotypes have been described. However, little details are known about the topology in patients from routine care. OBJECTIVES: To characterize the frequency and distribution of body sites affected by psoriasis in Germany based on high-resolution analysis. METHODS: Data from a national cross-sectional study (PsoHealth2) were analysed. Each practice consecutively recruited 20 patients independently of treatment...
November 14, 2018: British Journal of Dermatology
Yuan Wang, Jia Huo, Dingwei Zhang, Gang Hu, Yanfei Zhang
Psoriasis is a chronic disease which carries the emotional and social burden, promotes joint disability and raises comorbidity possibility in patients. Obesity is closely correlated with the occurrence of psoriasis and adipokines produced by adipose tissues were found to be critical culprits. Chemerin is one of them and its expression was increased in patients with psoriatic arthritis. In our hypothesis, chemerin might act on keratinocytes and promote an inflammatory response, which plays an essential role in psoriatic epidermis...
November 13, 2018: Journal of Cellular Biochemistry
Eric J Yang, Kristen M Beck, Wilson Liao
Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In Phase III clinical trials for each of these three indications, secukinumab has proven to be both highly efficacious and well-tolerated. However, several biologic medications are currently approved for the treatment of moderate-to-severe plaque psoriasis, and many demonstrate excellent efficacy and safety. Due to this wide selection, it is often unclear how to choose biologics for specific patients...
2018: Psoriasis: Targets and Therapy
Claudia Lasagni, Laura Bigi, Andrea Conti, Giovanni Pellacani
PURPOSE: Biologic therapy in psoriatic patients with multiple comorbidities is challenging due to worsening of associated diseases and possible side effects of concomitant medications. MATERIALS AND METHODS: We describe three patients with multiple comorbidities documenting successful treatment of psoriasis with secukinumab following failure of multiple conventional and biologic DMARDs. RESULTS: The first case is an obese 59-year-old woman (HBV + with latent tuberculosis) with arterial hypertension and 12-year history of breast cancer...
November 7, 2018: Journal of Dermatological Treatment
Ulf Lindström, Tor Olofsson, Sara Wedrén, Ilia Qirjazo, Johan Askling
Objectives: To assess the impact of extra-articular spondyloarthritis (SpA) manifestations (anterior uveitis, psoriasis and inflammatory bowel disease (IBD)), and of comorbidities, on tumour necrosis factor alpha inhibitor (TNFi) drug retention in ankylosing spondylitis (AS). Methods: We identified all bio-naïve patients with AS starting a first ever TNFi July 2006 to December 2015 from the Swedish Rheumatology Quality register and followed these from treatment start through December 2015...
2018: RMD Open
Victor Silva Mendes, Luís Otávio Miranda Cota, Amanda Almeida Costa, Alcione Maria Soares Dutra Oliveira, Fernando Oliveira Costa
BACKGROUND: The association between periodontitis and immuno-mediated inflammatory diseases has been widely studied and recognized each more over the past few years. The aim of this study was to evaluate the potential association between psoriasis and periodontitis, as well as the influence of risk variables in this association. METHODS: This case-control study included 756 individuals, 397 with psoriasis, and 359 controls. A full-mouth periodontal examination was performed, recording therefore plaque index, probing depth, clinical attachment level, and bleeding on probing...
November 2, 2018: Journal of Periodontology
Elena Pezzolo, Luigi Naldi
Smoking is the single most important cause of preventable mortality worldwide. Besides being associated with major cardiovascular and bronchopulmonary diseases, and several cancers, it has been linked with a number of immune-related conditions, including psoriasis and psoriatic arthritis (PsA) We aimed to summarize data on the role of smoking in the development and prognosis of psoriasis and PsA, pointing to the consequences in terms of disease management. Areas covered: Mechanisms, clinical manifestations, and comorbidities associated with smoking in psoriasis and PsA were reviewed by searching Medline, Embase and Cochrane Library databases for papers published between January 2000 and July 2018 using combination of terms...
October 31, 2018: Expert Review of Clinical Immunology
Karolina Kopeć-Pyciarz, Irena Makulska, Danuta Zwolińska, Łukasz Łaczmański, Wojciech Baran
Background: Psoriasis is currently regarded as a chronic systemic inflammatory disease associated with increased cardiovascular risk. Advanced glycation end products (AGEs) contribute to the development of atherosclerosis. Objectives: The aim of the study was the assessment of skin autofluorescence (SAF), as a measure of AGE accumulation, in individuals suffering from chronic plaque psoriasis without any comorbid conditions. Methods: A study group consisted of 70 patients with chronic plaque psoriasis without any comorbid conditions and 59 healthy controls, matched by age and gender...
2018: Mediators of Inflammation
Michitaro Hayakawa, Keisuke Izumi, Misako Higashida-Konishi, Mari Ushikubo, Masako Tsukamoto, Kumiko Akiya, Kazuhiro Araki, Hisaji Oshima
Tocilizumab (TCZ) is a humanized antihuman interleukin-6 (IL-6) receptor antibody used for the treatment of inflammatory diseases such as rheumatoid arthritis (RA). While TCZ could act as a therapeutic agent, it has a potential for inducing adverse drug events including psoriasis-like eruption. Seven cases with specific reference to TCZ-induced psoriasis eruption have been reported worldwide so far. In these cases, treatments with the same dosage of TCZ were either maintained or discontinued. Herein, we report a case involving a 74-year-old man diagnosed with rheumatoid factor-positive and anti-citrullinated protein antibody-positive RA with comorbidity of atopic dermatitis...
October 24, 2018: Rheumatology International
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"